Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

A number of other analysts have also recently weighed in on the stock. Chardan Capital reduced their price objective on shares of Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Royal Bank Of Canada cut their target price on shares of Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating for the company in a research report on Friday, November 7th. Jones Trading cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 11th. Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, October 28th. Finally, Bank of America cut their price objective on Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Nine analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $17.00.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $11.43 on Friday. The stock has a market capitalization of $1.32 billion, a P/E ratio of -2.68 and a beta of 2.05. The business has a 50-day moving average of $9.40 and a two-hundred day moving average of $12.73. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. During the same period last year, the business earned ($1.34) EPS. The firm’s revenue was up 51.6% compared to the same quarter last year. As a group, research analysts expect that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 34,146 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the sale, the executive vice president owned 101,528 shares of the company’s stock, valued at $935,072.88. This represents a 9.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 53,051 shares of company stock worth $488,600 over the last three months. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently bought and sold shares of NTLA. Headlands Technologies LLC acquired a new position in shares of Intellia Therapeutics in the 2nd quarter valued at $26,000. Blue Bell Private Wealth Management LLC bought a new stake in Intellia Therapeutics in the third quarter valued at about $30,000. Caitong International Asset Management Co. Ltd acquired a new position in Intellia Therapeutics in the third quarter worth about $30,000. Whipplewood Advisors LLC lifted its stake in Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after purchasing an additional 3,447 shares during the period. Finally, Advisory Services Network LLC acquired a new stake in Intellia Therapeutics during the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.